Large-scale circulating microRNA profiling for the liquid biopsy of prostate cancer

Fumihiko Urabe, Juntaro Matsuzaki, Yusuke Yamamoto, Takahiro Kimura, Tomohiko Hara, Makiko Ichikawa, Satoko Takizawa, Yoshiaki Aoki, Shumpei Niida, Hiromi Sakamoto, Ken Kato, Shin Egawa, Hiroyuki Fujimoto, Takahiro Ochiya

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Purpose: The high false-positive rate of prostate-specific antigen (PSA) may lead to unnecessary prostate biopsies. Therefore, the United States Preventive Services Task Force recommends that decisions regarding PSA-based screening of prostate cancer should be made with caution in men ages 55–69 years, and that men 70 years should not undergo PSA screening. Here, we investigated the potential of serum miRNAs as an accurate diagnostic method in patients with suspected prostate cancer. Experimental Design: Serum samples of 809 patients with prostate cancer, 241 negative prostate biopsies, and 500 patients with other cancer types were obtained from the National Cancer Center, Japan. Forty-one healthy control samples were obtained from two other hospitals in Japan. Comprehensive microarray analysis was performed for all samples. Samples were divided into three sets. Candidate miRNAs for prostate cancer detection were identified in the discovery set (n ¼ 123). A diagnostic model was constructed using combinations of candidate miRNAs in the training set (n ¼ 484). The performance of the diagnostic model was evaluated in the validation set (n ¼ 484). Results: In the discovery set, 18 candidate miRNAs were identified. A robust diagnostic model was constructed using the combination of two miRNAs (miR-17-3p and miR-1185-2-3p) in the training set. High diagnostic performance with a sensitivity of 90% and a specificity of 90% was achieved in the validation set regardless of the Gleason score and clinical tumor–node–metastasis stage. Conclusions: The model developed in this study may help improve the diagnosis of prostate cancer and reduce the number of unnecessary prostate biopsies.

Original languageEnglish
Pages (from-to)3016-3025
Number of pages10
JournalClinical Cancer Research
Volume25
Issue number10
DOIs
Publication statusPublished - 2019 Jan 1
Externally publishedYes

Fingerprint

MicroRNAs
Prostatic Neoplasms
Biopsy
Prostate-Specific Antigen
Prostate
Japan
Neoplasm Grading
Advisory Committees
Microarray Analysis
Serum
Neoplasms
Research Design

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Urabe, F., Matsuzaki, J., Yamamoto, Y., Kimura, T., Hara, T., Ichikawa, M., ... Ochiya, T. (2019). Large-scale circulating microRNA profiling for the liquid biopsy of prostate cancer. Clinical Cancer Research, 25(10), 3016-3025. https://doi.org/10.1158/1078-0432.CCR-18-2849

Large-scale circulating microRNA profiling for the liquid biopsy of prostate cancer. / Urabe, Fumihiko; Matsuzaki, Juntaro; Yamamoto, Yusuke; Kimura, Takahiro; Hara, Tomohiko; Ichikawa, Makiko; Takizawa, Satoko; Aoki, Yoshiaki; Niida, Shumpei; Sakamoto, Hiromi; Kato, Ken; Egawa, Shin; Fujimoto, Hiroyuki; Ochiya, Takahiro.

In: Clinical Cancer Research, Vol. 25, No. 10, 01.01.2019, p. 3016-3025.

Research output: Contribution to journalArticle

Urabe, F, Matsuzaki, J, Yamamoto, Y, Kimura, T, Hara, T, Ichikawa, M, Takizawa, S, Aoki, Y, Niida, S, Sakamoto, H, Kato, K, Egawa, S, Fujimoto, H & Ochiya, T 2019, 'Large-scale circulating microRNA profiling for the liquid biopsy of prostate cancer', Clinical Cancer Research, vol. 25, no. 10, pp. 3016-3025. https://doi.org/10.1158/1078-0432.CCR-18-2849
Urabe F, Matsuzaki J, Yamamoto Y, Kimura T, Hara T, Ichikawa M et al. Large-scale circulating microRNA profiling for the liquid biopsy of prostate cancer. Clinical Cancer Research. 2019 Jan 1;25(10):3016-3025. https://doi.org/10.1158/1078-0432.CCR-18-2849
Urabe, Fumihiko ; Matsuzaki, Juntaro ; Yamamoto, Yusuke ; Kimura, Takahiro ; Hara, Tomohiko ; Ichikawa, Makiko ; Takizawa, Satoko ; Aoki, Yoshiaki ; Niida, Shumpei ; Sakamoto, Hiromi ; Kato, Ken ; Egawa, Shin ; Fujimoto, Hiroyuki ; Ochiya, Takahiro. / Large-scale circulating microRNA profiling for the liquid biopsy of prostate cancer. In: Clinical Cancer Research. 2019 ; Vol. 25, No. 10. pp. 3016-3025.
@article{35961f43a19b4b83a5fcd34aaf4a7e73,
title = "Large-scale circulating microRNA profiling for the liquid biopsy of prostate cancer",
abstract = "Purpose: The high false-positive rate of prostate-specific antigen (PSA) may lead to unnecessary prostate biopsies. Therefore, the United States Preventive Services Task Force recommends that decisions regarding PSA-based screening of prostate cancer should be made with caution in men ages 55–69 years, and that men 70 years should not undergo PSA screening. Here, we investigated the potential of serum miRNAs as an accurate diagnostic method in patients with suspected prostate cancer. Experimental Design: Serum samples of 809 patients with prostate cancer, 241 negative prostate biopsies, and 500 patients with other cancer types were obtained from the National Cancer Center, Japan. Forty-one healthy control samples were obtained from two other hospitals in Japan. Comprehensive microarray analysis was performed for all samples. Samples were divided into three sets. Candidate miRNAs for prostate cancer detection were identified in the discovery set (n ¼ 123). A diagnostic model was constructed using combinations of candidate miRNAs in the training set (n ¼ 484). The performance of the diagnostic model was evaluated in the validation set (n ¼ 484). Results: In the discovery set, 18 candidate miRNAs were identified. A robust diagnostic model was constructed using the combination of two miRNAs (miR-17-3p and miR-1185-2-3p) in the training set. High diagnostic performance with a sensitivity of 90{\%} and a specificity of 90{\%} was achieved in the validation set regardless of the Gleason score and clinical tumor–node–metastasis stage. Conclusions: The model developed in this study may help improve the diagnosis of prostate cancer and reduce the number of unnecessary prostate biopsies.",
author = "Fumihiko Urabe and Juntaro Matsuzaki and Yusuke Yamamoto and Takahiro Kimura and Tomohiko Hara and Makiko Ichikawa and Satoko Takizawa and Yoshiaki Aoki and Shumpei Niida and Hiromi Sakamoto and Ken Kato and Shin Egawa and Hiroyuki Fujimoto and Takahiro Ochiya",
year = "2019",
month = "1",
day = "1",
doi = "10.1158/1078-0432.CCR-18-2849",
language = "English",
volume = "25",
pages = "3016--3025",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "10",

}

TY - JOUR

T1 - Large-scale circulating microRNA profiling for the liquid biopsy of prostate cancer

AU - Urabe, Fumihiko

AU - Matsuzaki, Juntaro

AU - Yamamoto, Yusuke

AU - Kimura, Takahiro

AU - Hara, Tomohiko

AU - Ichikawa, Makiko

AU - Takizawa, Satoko

AU - Aoki, Yoshiaki

AU - Niida, Shumpei

AU - Sakamoto, Hiromi

AU - Kato, Ken

AU - Egawa, Shin

AU - Fujimoto, Hiroyuki

AU - Ochiya, Takahiro

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Purpose: The high false-positive rate of prostate-specific antigen (PSA) may lead to unnecessary prostate biopsies. Therefore, the United States Preventive Services Task Force recommends that decisions regarding PSA-based screening of prostate cancer should be made with caution in men ages 55–69 years, and that men 70 years should not undergo PSA screening. Here, we investigated the potential of serum miRNAs as an accurate diagnostic method in patients with suspected prostate cancer. Experimental Design: Serum samples of 809 patients with prostate cancer, 241 negative prostate biopsies, and 500 patients with other cancer types were obtained from the National Cancer Center, Japan. Forty-one healthy control samples were obtained from two other hospitals in Japan. Comprehensive microarray analysis was performed for all samples. Samples were divided into three sets. Candidate miRNAs for prostate cancer detection were identified in the discovery set (n ¼ 123). A diagnostic model was constructed using combinations of candidate miRNAs in the training set (n ¼ 484). The performance of the diagnostic model was evaluated in the validation set (n ¼ 484). Results: In the discovery set, 18 candidate miRNAs were identified. A robust diagnostic model was constructed using the combination of two miRNAs (miR-17-3p and miR-1185-2-3p) in the training set. High diagnostic performance with a sensitivity of 90% and a specificity of 90% was achieved in the validation set regardless of the Gleason score and clinical tumor–node–metastasis stage. Conclusions: The model developed in this study may help improve the diagnosis of prostate cancer and reduce the number of unnecessary prostate biopsies.

AB - Purpose: The high false-positive rate of prostate-specific antigen (PSA) may lead to unnecessary prostate biopsies. Therefore, the United States Preventive Services Task Force recommends that decisions regarding PSA-based screening of prostate cancer should be made with caution in men ages 55–69 years, and that men 70 years should not undergo PSA screening. Here, we investigated the potential of serum miRNAs as an accurate diagnostic method in patients with suspected prostate cancer. Experimental Design: Serum samples of 809 patients with prostate cancer, 241 negative prostate biopsies, and 500 patients with other cancer types were obtained from the National Cancer Center, Japan. Forty-one healthy control samples were obtained from two other hospitals in Japan. Comprehensive microarray analysis was performed for all samples. Samples were divided into three sets. Candidate miRNAs for prostate cancer detection were identified in the discovery set (n ¼ 123). A diagnostic model was constructed using combinations of candidate miRNAs in the training set (n ¼ 484). The performance of the diagnostic model was evaluated in the validation set (n ¼ 484). Results: In the discovery set, 18 candidate miRNAs were identified. A robust diagnostic model was constructed using the combination of two miRNAs (miR-17-3p and miR-1185-2-3p) in the training set. High diagnostic performance with a sensitivity of 90% and a specificity of 90% was achieved in the validation set regardless of the Gleason score and clinical tumor–node–metastasis stage. Conclusions: The model developed in this study may help improve the diagnosis of prostate cancer and reduce the number of unnecessary prostate biopsies.

UR - http://www.scopus.com/inward/record.url?scp=85063113227&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063113227&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-18-2849

DO - 10.1158/1078-0432.CCR-18-2849

M3 - Article

C2 - 30808771

AN - SCOPUS:85063113227

VL - 25

SP - 3016

EP - 3025

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 10

ER -